In vitro study | BMS-935177 the selectivity of BTK is more than 50 times higher than that of SRC kinase family members. In Ramos B cells, BMS-935177 inhibited calcium flux; In peripheral blood B lymphocytes stimulated by anti-IgM and anti-IgG, BMS-935177 inhibited cell surface expression of cd69. However, BMS-935177 of B cells stimulated by CD40 receptor and ligand had no effect on CD69 expression. In PBMCs, BMS-935177 can effectively inhibit the production of TNF-α, IC50 is 14 nM. |
In vivo study | The plasma protein binding rate was high in BMS-935177 of the tested species, and the free drug ratio was less than 1% in humans. In preclinical testing, BMS-935177 had good oral activity, whether administered in suspension or in solution, despite its poor water solubility. Administered as a solution, the oral bioavailability in rats, mice, dogs, and cynomolgus monkeys was 84%-100% BMS-935177, while in single intravenous administration experiments, has a low clearance rate in vivo. At a dose of 2 mg/kg I. V. In mice and rats, T BMS-935177 was 4 h and 5.1 h, respectively. |